Alumis Inc.
XNAS:ALMS 10:20:02 AM EDT
| Market Cap (Intraday) | 3.16B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $23.46 |
| 50-Day MA | $25.71 |
| 200-Day MA | $12.43 |
Alumis Inc. Stock, XNAS:ALMS
280 East Grand Avenue, San Francisco, California 94080
United States of America
Phone: +1.650.231.6625
Number of Employees:
Description
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.